POM-V Prescription Required

RESPIPORC FLUpan H1N1 Suspension for Injection for Pigs

Active ingredient: Swine influenza virus

Form

Injection

Species

Pigs

Manufacturer

Ceva Animal Health Ltd

VMD MA No.

15052/5017

What it's used for

Active immunisation of pigs from the age of 8 weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and viral excretion. On...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Swine influenza virus

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

RESPIPORC FLUpan H1N1 Suspension for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Active immunisation of pigs from the age of 8 weeks onwards against pandemic
H1N1 porcine influenza virus to reduce viral lung load and viral excretion.
Onset of immunity: 7 days after primary vaccination.
Duration of immunity: 3 months after primary vaccination.

For intramuscular use.
Piglets:
2 injections of one dose (1 ml) from the age of 56 days, with an interval of 3 weeks
between injections.
The efficacy of revaccination has not been investigated and therefore no
revaccination schedule is proposed.
Maternally-derived antibodies in piglets interfere with the RESPIPORC FLUpan
H1N1 mediated immunity. Generally, maternally-derived antibodies induced by
vaccination last for approximately 5–8 weeks after birth.

In cases of exposure of the sows to antigens (from either field infections and/or
vaccination) the antibodies transmitted to the piglets can interfere with active
immunisation at 12 weeks of age. In such cases the piglets should be vaccinated
after the age of 12 weeks.
Gilts and sows:
Primary vaccination: 2 injections of one dose (1 ml) with an interval of 3 weeks
between injections and up to 3 weeks before expected farrowing or during lactation.
The efficacy of single dose revaccination has not been investigated and therefore no
single dose revaccination schedule is proposed for further pregnancies.

None.

Common
(1 to 10 animals / 100 animals
treated):
Injection site swelling
Hyperthermia
.
transient swelling up to 2 cm
, resolves within 5 days.
transient increase in rectal temperature not exceeding 2°C, does not persist for
more than one day.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See also section 16 of the package leaflet for contact
details.

Vaccinate healthy animals only.

Revised January 2025
AN: 02713/2023 & 02710/2023

Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Revised January 2025
AN: 02713/2023 & 02710/2023

Store in a refrigerator (2 ºC−8 ºC). Do not freeze.
Keep the vial in the outer carton in order to protect from light.

Zero days.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals, inactivated viral vaccines for pigs,
porcine influenza virus.
ATCvet code: QI09AA03.
The vaccine stimulates an active immunity against pandemic porcine influenza
A/Jena/VI5258/2009 (H1N1)pandemic09-like virus. It induces neutralising and
haemagglutination-inhibiting antibodies against this subtype.
The antibody responses mentioned in the following have been documented in pigs
without maternally-derived immunity. Neutralising antibodies in serum have been
detected in more than 75% of the immunised pigs on day 7 after primary
immunisation lasting in more than 75% of the pigs for over 3 months.
Haemagglutination-inhibiting antibodies have been detected in 15–100% of the
immunised pigs on day 7 after primary immunisation which disappeared in the
majority of animals within 1 to 4 weeks thereafter.

Revised January 2025
AN: 02713/2023 & 02710/2023
Efficacy of the vaccine was examined in laboratory challenge studies in pigs without
maternally-derived antibodies and was demonstrated against the following strains:
FLUAV/Hamburg/NY1580/2009(H1N1)pdm09 (human origin),
FLUAV/swine/Schallern/IDT19989/2014 (H1N1)pdm09 (swine origin) and
FLUAV/sw/Teo(Spain)/AR641/2016 (H1N1)pdm09 (swine origin).

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.